HCM
GILD icon

Highfields Capital Management’s Gilead Sciences GILD Stock Holding History

Highfields Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-348,100
Closed -$24.9M – 74
2016
Q4 		$24.9M Buy
+348,100
New +$25.9M 0.21% 59

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Highfields Capital Management's GILD Position: Q1 2017 in Review

Highfields Capital Management sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 348,100 shares — an estimated $24.9M sold.

Highfields Capital Management first reported a position in GILD in Q4 2016 and held it in 1 quarter. The position peaked at $24.9M in Q4 2016. 1,526 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Highfields Capital Management reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Highfields Capital Management sold 348,100 Gilead Sciences shares in Q1 2017, an estimated $24.9M.
  • Highfields Capital Management first reported a position in Gilead Sciences in Q4 2016 and held it in 1 quarter.
  • Highfields Capital Management's Gilead Sciences position peaked at $24.9M in Q4 2016.
  • 1,526 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Highfields Capital Management's 13F filing for Q1 2017, filed 15 May 2017.